Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

Completed · Phase 3

Conditions studied: Breast Neoplasms

In brief

To determine the safety and efficacy of LY353381 when compared to tamoxifen in women with advanced or metastatic breast cancer.

Key facts

Study ID

NCT00034125

Run by

Eli Lilly and Company

Last updated by the study team

2006-07-19

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Locally advanced or metastatic breast cancer
• Bi-dimensionally measurable disease

You may not qualify if…

• Prior hormonal therapy

Where it is running

• Study site — Miami, Florida, United States
• Study site — Shreveport, Louisiana, United States
• Study site — Boston, Massachusetts, United States
• Study site — Nashville, Tennessee, United States
• Study site — Capital Federal, Buenos Aires, Argentina
• Study site — Ciudad de Buenos Aires, Buenos Aires F.D., Argentina
• Study site — Las Condes, Santiago Metropolitan, Chile
• Study site — Providencia, Santiago Metropolitan, Chile
• Study site — Ahmedabab, Gujarat, India
• Study site — Mexico City, Benito Juarez, Mexico
• Study site — Colima, Colima, Mexico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.